Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib

Medical Oncology

Volumn 28, Issue 4, 2011, Pages 1527-1529

  Molina, Ana M ^a   Ginsberg, Michelle S ^a   Motzer, Robert J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Everolimus; Kidney cancer; Metastatic; mTOR; Renal cell carcinoma; Sunitinib

Indexed keywords

EVEROLIMUS; PLACEBO; SUNITINIB;

AGED; ALCOHOL CONSUMPTION; ANAMNESIS; ANKLE EDEMA; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LIVER METASTASIS; MALE; METASTASIS; METASTASIS RESECTION; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; RASH; STOMATITIS; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; ARTHRITIS, RHEUMATOID; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INDOLES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; SIROLIMUS;

EID: 84655176768     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9640-y     Document Type: Article

References (11)

1. B Escudier 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134
2. RJ Motzer 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124
3. Sternberg CN, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2009;27:15s (suppl; abstr 5021).
4. Hudes G, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
5. RJ Motzer 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial Lancet 372 449 456
6. Motzer RJ, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(118). doi: 10.1002/cncr.25219.
7. RJ Motzer 2009 NCCN clinical practice guidelines in oncology: kidney cancer J Natl Compr Canc Netw. 7 618 630
8. TM de Reijke 2009 EORTC-GU group expert opinion on metastatic renal cell cancer Eur J Cancer 45 765 773
9. Hutson TE, et al. Everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the RECORD-1 study. Presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, March 5-7, 2010, San Francisco, CA. Abstract and Poster 362.
10. RJ Amato 2009 A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer Cancer. 115 2438 2446
11. Mackenzie MJ, et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann Oncol. doi: 10.1093/annonc/mdq320. http://annonc. oxfordjournals.org/content/early/2010/06/30/annonc.mdq320.full.pdf+html.